-astatine containing radiotherapeutics for the treatment of cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 29, 2019
Grant Date -
Jun 14, 2018
app pub date -
Apr 26, 2016
filing date -
May 4, 2015
priority date (Note) -
In Force
status (Latency Note)
Importance
Calculated Rating
|
US Family Size
|
Non-US Coverage
|
Abstract
Described herein is an alpha-emitting radionuclide, 211At, which has been incorporated into a selective sigma-2 ligand moiety to provide cytotoxic capabilities to a chemical compound. As described herein, a compound of formula (I), wherein R1-R4, m, and n are defined herein, was prepared and utilized in in vitro and in vivo tumor targeting of alpha-emitting sigma-2 ligand in a breast cancer model. In one embodiment, the compound is 5-(211At)—N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2,3-dimethoxybenzamide.
First Claim
Other Claims data not available
Family
+
−
| Country | kind | publication No. | Filing Date |
|---|---|---|---|
| WO | A1 | WO2016178852 | Apr 26, 2016 |
International Classification(s)
- 2016 Application Filing Year
- A61K Class
- 19101 Applications Filed
- 13019 Patents Issued To-Date
- 68.16 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 1 Citation Count
- A61K Class
- 58.87 % this patent is cited more than
- 6 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Apr 29, 2027 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Apr 29, 2031 |
